This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.
18-64 years of age
HbA1c <= 9.0%.
Body Mass Index (BMI) between 18.5 and 29.0 kg/m²
treated with a stable insulin regimen for at least 2 months, in a dose > 0.2 and < 1.2 U/kg/day
blood pressure outside the range 90 to 140 mmHg (systolic) or 50 to 99 mmHg (diastolic)
clinically significant concomitant diseases
recurrent severe hypoglycemia (more than 1 severe hypoglycemic episode requiring assistance from another person within 180 days before screening)
hypoglycemia unawareness